Q1 Fiscal Year 2026
- Very good equipment book-to-bill ratio of 1.12
- Imaging comparable revenue growth of 5.7%; adjusted EBIT margin of 21.6%
- Precision Therapy comparable revenue growth of 5.9%; adjusted EBIT margin of 14.9%
- Diagnostics comparable revenue decline of 3.1% mainly due to a structural change in the China region market environment; adjusted EBIT margin of 2.1%
- Overall comparable revenue growth of 3.8%
- Adjusted EBIT margin of 15.0%, on prior-year level
- Adjusted basic earnings per share of 鈧0.49, almost at prior-year level despite tariff and currency effects
- Free cash flow of 鈧330 million
Outlook for Fiscal Year 2026
We confirm our expectation of comparable revenue growth of between 5% to 6% compared with fiscal year 2025 and adjusted basic earnings per share to be between 鈧2.20 and 鈧2.40.
Bernd Montag, CEO of Siemens Healthineers AG:
鈥漌e had a very good start, with higher profit and profitability in our Imaging and Precision Therapy core despite significant headwinds from foreign-exchange rates and tariffs. Diagnostics continues to feel the effects of a transition phase in the Chinese market.鈥